company logo

Strategic Account Manager in Virtual / Travel



Account Management


8 - 10 years

Job Description


This position is responsible for achieving the sales expectations/quota of an assigned geography with a specific focus on SINUVA focal accounts. Success is realized by building strong customer relationships, exceeding sales targets via conducting consultative sales calls and utilizing solid product/technical knowledge, following a targeted call plan, and developing/maintaining a comprehensive business plan that is focused on maintenance of base business, and new customer cultivation.


  • Develop and execute the tactical planning and strategic execution of a business plan and sales objectives for target accounts in the assigned geography.
  • Drive all daily sales objectives, which are focused on growth in assigned geography. This includes new account targeting, cultivation, and launch planning/execution.
  • Strong collaboration and partnership with RM and TM counterparts in defined geograp
See More

Valid through: 2020-2-24

About Intersect ENT

Intersect ENT (NASDAQ: XENT) is a publicly traded health care equipment company based in Menlo Park, California. It manufactures drug-delivery devices used by Ear, Nose & Throat (ENT) clinicians in the treatment of sinusitis. Intersect ENT is best known for developing the first bioabsorbable drug-eluting sinus stent PROPEL, which delivers anti-inflammatory medication directly to the sinuses. The company holds over 20 issued patents in the United States and more than 80 patents and patent applications worldwide. The company was named on the Forbes list of Americas Most Promising Companies and was also on the Firece 15 list of Most Promising Companies in 2013. Intersect ENT was founded in 2003 by Don Eaton who conceived of the product over dinner with ENT surgeon, Mary Lynn Moran, MD. The company received its Series A funding in 2006, prompting the hiring of a team to develop the product. It was originally headquartered in Palo Alto, California, then moved to Menlo Park, CA in April 2012 to a new 32,000-foot facility. The facility houses all of its business and manufacturing operations. Prior to the company becoming public, venture capital investors in the company include medical device company Medtronic Inc. and venture capital firms Kleiner Perkins Caufield & Byers, U.S. Venture Partners, PTV Sciences and Norwest Venture Partners. In 2013 it received $30 million in a series D round of financing led by Norwest Venture Partners, and included all named investors. Intersect ENT announced that the funding would be used for commercial expansion of its PROPEL and PROPEL mini devices, as well as clinical studies for additional devices manufactured to add to the companys portfolio of drug-delivery products.
Total Jobs:
Average Pay:
Total value of jobs:
% Masters:
* Ladders Estimates